UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

May 17, 2022

(Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS

	(Exact N	Name of Registrant as Specified in its Chart	er)
Delaware (State or other jurisdiction of Incorporation)		1-11353	13-3757370
		(Commission File Number)	(I.R.S. Employer Identification No.)
	358 South Main Street		
Burlin	0 /	rolina	27215
(4	Address of principal executive offices)		(Zip Code)
	(Registrant's to	elephone number including area code) 336-	229-1127
Check the appropri following provision		is intended to simultaneously satisfy the	filing obligation of the registrant under any of the
□ Soliciting mat□ Pre-commence	•	` ,	* **
Securities registered	d pursuant to Section 12(b) of the Excha	ange Act.	
Title of Each Class Common Stock, \$0.	<i>e</i> ,	of exchange on which registered rk Stock Exchange	
	nark whether the registrant is an emergin b-2 of the Securities Exchange Act of 19 Emerging growth company		of the Securities Act of 1933 (§230.405 of this
		the registrant has elected not to use the extension to Section 13(a) of the Exchange Act. \Box	ended transition period for complying with any new
Item 7.01	Regulation FD Disclosure		
	H), a leading global life sciences com JBS 2022 Global Healthcare Conference		he executive management team will participate in a
A live webcast of the	ne fireside chat will be available via the	Labcorp Investor Relations website and arc	hived for replay.
Item 9.01	Financial Statements and Exhibits.		
Exhibit Exhibit 99.1	Exhibit Name Press Release dated May 17, 2022 iss	sued by Labcorp	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

<u>LABORATORY CORPORATION OF AMERICA HOLDINGS</u> Registrant

By: /s/ SANDRA VAN DER VAART

Sandra van der Vaart

Executive Vice President, Chief Legal Officer and Corporate Secretary

May 17, 2022



FOR IMMEDIATE RELEASE

LabCorp Contacts:

Investors: Chas Cook — 336-436-5076

Investor@Labcorp.com

Media: Christopher Allman-Bradshaw - 336-436-8263

Media@Labcorp.com

LABCORP TO SPEAK AT THE UBS 2022 GLOBAL HEALTHCARE CONFERENCE

BURLINGTON, N.C., May 17, 2022 — Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a fireside chat at the UBS 2022 Global Healthcare Conference on Tuesday, May 24 at 2:45 p.m (ET).

A live webcast of the fireside chat will be available via the Labcorp Investor Relations website and archived for replay.

About Labcorp

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With more than 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of \$16 billion in 2021. Learn more about us at www.labcorp.com or follow us on LinkedIn and Twitter @Labcorp.